TO STUDY THE THERAPEUTIC MANAGEMENT, DRUG RELATED PROBLEMS AND CONCOMITANT USE OF DRUGSIN PATIENTS WITH CANCER

Pramila P.; Anju Abraham; Sunita Pawar; Vibha Bafna; Monika S Bansal

doi:10.22159/ijpps.2017v9i6.18207

Authors

Pramila P. Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Pharm.D Interns
Anju Abraham Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Pharm.D Interns
Sunita Pawar Asst. Professor, Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune
Vibha Bafna Assistant Professor of Paediatric Department, Bharati Hospital and Research Centre, Pune
Monika S Bansal Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Pharm.D Interns

DOI:

https://doi.org/10.22159/ijpps.2017v9i6.18207

Keywords:

Cancer, Cytotoxics, Chemotherapeutic drugs, Concomitant drugs, Drug-related problems

Abstract

Objective: To study the prescribing patterns of chemotherapeutic drugs, concomitant drugs and to determine the drug-related problems in cancer patients.

Methods: A prospective and retrospective observational study was conducted over a period of 6 mo in a tertiary care teaching hospital, Pune after ethical approval and informed consent. Patients were then interviewed for patient information like demographics, treatment, and associated drug related problems using specially designed proforma and then required data was introduced in Microsoft excel spreadsheets.

Results: Out of 60 patients 50 were enrolled in this study during which 9 different sites of cancer were examined. The maximum number of patients with cancer resides in the age group of 51-60 y (32%) and more common in females in 27 (54%). The most prevalent risk factor and co-morbidity encountered were tobacco chewing 13 (26%) and hypertension 8 (16%), respectively. On the further evaluation of data, the findings suggested that the majority of patients were prescribed with an alkylating group of anti-neoplastic agents, paclitaxel+platinum-based compound regimen, and the drug paclitaxel. On screening, 167 drug interactions were observed, of these most of the interactions were in the moderate category. The most common organ system affected was gastrointestinal system 135 (30.80%) whereas the prevalent toxicity was hyperuricemia. Polypharmacy was not observed, whereas antacid (ranitidine) was frequently prescribed during hospitalisation and discharge.

Conclusion: This study has highlighted certain facts and drawbacks in medication-related care which can be addressed by conducting future studies in cancer care in order to provide patient-specific outcomes.

Downloads

Download data is not yet available.

References

Sanigaram V, Lingampally S, Boyana A, Vurumadla S. A prospective study on clinical evaluation, treatment pattern and adverse effects of anticancer drugs in various gynaecological cancer patients. Asian J Pharm Clin Res 2015;8:125-31.

Sankaranarayanan R. Cancer prevention and care in India: an unfinished agenda. Lancet Oncol 2014;15:554-5.

Saka S, Singh A, Sharma N. Potential anti-cancer superfoods: a minireview. Int J Curr Pharm Res 2016;8:19-21.

Ali I, Waseem W, Saleem K. Cancer scenario in India with future perspectives. Cancer Ther 2011;8:56-70.

Gupta M, Dahiya J, Marwaha RK, Dureja H. Therapies in cancer treatment: an overview. Int J Pharm Pharm Sci 2015;7:1-9.

Ramalakshmi S, Ramesh A, Sahini K, Babu K, Kousalya K, Saranya P. A study on prescribing trends of supportive care drugs used in cancer chemotherapy in a tertiary care teaching hospital. Indian J Pharm Practice 2013;6:36-9.

Patel S, Singh N, Kumar L. Anticancer role of antidiabetic drug metformin in ovarian cancer cells. Int J Cancer Ther Oncol 2016;4:1-8.

Ali M, Mahmoud A, Abdel-Halim A, Fyiad A. Anti-cancer effect of some prepared sulfated oligosaccharides on three different human cancer cell lines. Asian J Pharm Clin Res 2014;7 Suppl 1:168-76.

Kirthi C, Afzal A, Reddy M, Ali S, Yerramilli A, Sharma S. A study on the adverse effects of anticancer drugs in an oncology center of a tertiary care hospital. Int J Pharm Pharm Sci 2014;6, Suppl 2:580-3.

Arora S, Agarwal S, Singhal S. Anticancer activities of thiosemicarbazides/thiosemicarbazones: a review. Int J Pharm Pharm Sci 2014;6:34-41.

Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage 2014;48:1145-59.

Pentareddy MR, AVS Suresh, Shailendra D, Subbaratnam Y, Prasuna G, DTV Naresh, et al. Prescription patterns of anticancer drugs in a tertiary care hospital. J Evidence Based Med Healthcare 2015;2:3001-9.

Kulkarni MD, Hussaini S, Padwal SL, Khandelwal P, Doifode S, More P, et al. Drug utilization review of anticancer drugs in cancer outpatient department of the Government Medical College, Aurangabad. Int J Basic Clin Pharmacol 2014;3:879-83.

Khan GM, Thapa RK, Adhikari DS, Rajbhandari M, Dwa P, Shrestha S, et al. Evaluation of cancer prevalence and cytotoxic medication prescribing in the central region of Nepal. Kathmandu University J Sci Eng Technol 2013;9:189-99.

Dave D, Pillai A, Shah D, Agarwal S, Goel A. An analysis of utilization pattern of anticancer drugs in diagnosed cases of carcinoma in a tertiary care teaching hospital. Int J Basic Appl Med Sci 2014;4:251-9.

Vrabel M. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. Clin J Oncol Nurs 2007;11:809-13.

Sneha G, Aparna S, BNVB Sri Lakshmi, Varma S, Naidu DSR. Adjunctive drug utilization pattern in the oncology department of a tertiary care hospital in South India. Indo Am J Pharm Res 2015;5:1297-303.

Sloan FA, Gelband H. Cancer control opportunities in low-and middle-income countries. Washington (DC): National Academies Press (US); 2007. p. 1-4.

Piccirillo J, Tierney R, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-7.

Nazmul H, Mesbah U, Rafiquzzaman Md, Chowdhury S, Wahed B. Distribution of types of cancer and patterns of cancer treatment among the patients at various hospitals in Dhaka division, Bangladesh. Int Res J Pharm 2012;3:219-22.

Kiebert GM, Stiggelbout AM, Kievit J, Leer JW, Van de Velde CJ, de Haes HJ. Choices in oncology: factors that influence patients' treatment preference. Qual Life Res 1994;3:175-82.

Kannan G, Anitha R, Rani V, Thennarasu P, Alosh J, Vasantha J, et al. A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital. J Postgrad Med 2011;57:206-10.

Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-Â¬drug interactions between antiÂ¬cancer agents and community pharmacy dispensed drugs. Pharm World Sci 2010;32:575-80.

Prasad A, Datta P, Bhattacharya J, Pattanayak C, Chauhan A, Panda P. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India. J Pharmacovigilance 2013;1:1-4.

Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 2004;12:626-33.

Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-83.

Shek TW Luk IS, Ma L, Cheung KL. Paclitaxel-induced cardiotoxicity. An ultrastructural study. Arch Pathol Lab Med 1996;120:89-91.

Korc-Grodzicki B, Boparai M, Lichtman S. Prescribing for older patients with cancer. Clin Adv Hematol Oncol 2014;12:309-18.

Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007;32:169-75.